Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells

[Image: see text] The CD44 receptor is common among many cancer types where overexpression is synonymous with poor prognosis in prostate, glioma, and breast cancer. More notably CD44 overexpression has been shown in a number of different cancer stem cells (CSC) which are present in many solid tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Beals, Nathan, Thiagarajan, Praveena S., Soehnlen, Eric, Das, Arijit, Reizes, Ofer, Lathia, Justin D., Basu, Soumitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044869/
https://www.ncbi.nlm.nih.gov/pubmed/30023561
http://dx.doi.org/10.1021/acsomega.7b01168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044869/
https://www.ncbi.nlm.nih.gov/pubmed/30023561
http://dx.doi.org/10.1021/acsomega.7b01168

Ejemplares similares